Life Sciences Partners (LSP) has held a final close for its sixth life-sciences-dedicated fund on its $600m hard-cap.
The fund was launched in March 2018 with a $450m target and held a first close on €410m in November 2018.
The vehicle is larger than its predecessor, which closed on its $280m hard-cap, surpassing its $170m target, in June 2016.
LPS has raised $2.5bn since it started to invest in life sciences in 1988. The group has offices in Amsterdam, Munich and Boston. Alongside LSP 6, the firm is investing from its $300m Health Economics Fund, and its $200m public fund and mandates.
LSP's stand-out deals include Argenx, Crucell, Kudos, Movetis, Neuravi, Okairos, Prosensa, Qiagen and Zealand Pharma.
LSP 6 will invest in 15-18 predominantly European companies developing new medications and medical technologies. The fund has already made 12 investments.
LSP 6 attracted capital from a diverse investor base including pension funds, insurance companies, wealth managers, government funds and family offices. Among others, it received commitments from Bristol Myers Squibb and Otsuka Pharmaceutical.
Life Sciences Partners – René Kuijten (managing partner).
Fund has an €80m target and invests in seed, series-A and series-B rounds in the space technology sector
Sale follows a competitive process initiated in July 2019 as part of the company's restructuring
Bolt-on of cable installation market peer is subject to competition authority approval
GP acquired a majority stake in the Romanian recycling business in April 2016